Evidence map›Paper›PMID 27518324›Full record

ArticleACS combinatorial science2016

Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments.

Sina Haftchenary, Shawn D Nelson, Laura Furst, Sivaraman Dandapani, Steven J Ferrara, Žarko V Bošković, Samuel Figueroa Lazú, Adrian M Guerrero, Juan C Serrano, DeMarcus K Crews and 6 more

Abstract read
In one paragraph

Article in ACS combinatorial science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Design and Synthesis of 56 Shape-Diverse 3D Fragments.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020
    Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sina HaftchenaryCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Shawn D NelsonCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Laura FurstCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Sivaraman DandapaniCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Steven J FerraraCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Žarko V BoškovićCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Samuel Figueroa LazúCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Adrian M GuerreroCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Juan C SerranoCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
DeMarcus K CrewsCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Cristina BrackeenCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Jeffrey MowatBayer Pharma AG , Drug Discovery, Müllerstraße, 178, 13353 Berlin, Germany.
Thomas BrumbyBayer Pharma AG , Drug Discovery, Müllerstraße, 178, 13353 Berlin, Germany.
Marcus BauserBayer Pharma AG , Drug Discovery, Müllerstraße, 178, 13353 Berlin, Germany.
Stuart L SchreiberCenter for the Science of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.
Andrew J PhillipsCenter for the Development of Therapeutics, Broad Institute , 415 Main Street, Cambridge, Massachusetts 02142, United States.

Funding

SYNTHESIS OF MATERIALS WITH PHYSIOLOGICAL PROPERTIESR01GM038627 · NIGMS · YALE UNIVERSITY · PI SCHREIBER, STUART L · 1987 to 2017
$10.5M
Howard Hughes Medical InstituteNIGMS NIH HHS R01 GM038627
6 · The paper itself

Abstract

Efficient syntheses of chiral fragments derived from chiral amino alcohols are described. Several unique scaffolds were readily accessed in 1-5 synthetic steps leading to 45 chiral fragments, including oxazolidinones, morpholinones, lactams, and sultams. These fragments have molecular weights ranging from 100 to 255 Da and are soluble in water (0.085 to >15 mM).

Indexed as

Amino AlcoholsDrug DiscoveryHumansLactamsMolecular WeightMorpholinesNaphthalenesulfonatesOxazolidinonesStereoisomerismAmino AlcoholsLactamsMorpholinesNaphthalenesulfonatesnaphthosultoneOxazolidinonesamino alcoholschiral fragmentsdrug discoveryfragment-based lead discovery

Identifiers

PMID27518324
PMCPMC5022782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.